NORTH CHICAGO, Ill., Oct. 2, 2026 /PRNewswire/ — Saros Therapeutics, a company in Rosalind Franklin University of Medicine and Science’s (RFU) Helix 51 biomedical incubator, has received its second National Cancer Institute (NCI) Phase II award of approximately $2 million to advance a…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
